Literature DB >> 25037512

Preconception considerations.

Lynn L Simpson1.   

Abstract

Heart disease complicates 1-2% of pregnancies, and in preparation for pregnancy, these women should receive comprehensive preconception counseling. Risks to the mother and potential risks to the offspring secondary to the type and severity of maternal cardiac disease, its inheritance pattern, required medical therapy, and palliative or corrective procedures that may be needed must be considered. Life expectancy and the ability to care for a child are somber issues that must be addressed when serious cardiac conditions exist. Pregnancy is still contraindicated in women with pulmonary hypertension, severe systemic ventricular dysfunction, dilated aortopathy, and severe left-sided obstructive lesions, but advances in medical and surgical management have resulted in an increasing number of patients with cardiac disorders who are interested in pursuing pregnancy. A multidisciplinary approach can best determine whether acceptable outcomes can be expected and what management strategies may improve the prognosis for women with heart disease and their offspring.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  counseling; maternal heart disease; maternal risks; perinatal risks

Mesh:

Year:  2014        PMID: 25037512     DOI: 10.1053/j.semperi.2014.04.011

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  2 in total

1.  Pregnancy in Advanced Kidney Disease: Clinical Practice Considerations on a Challenging Combination.

Authors:  Rozemarijn Snoek; Rieke van der Graaf; Jildau R Meinderts; Franka van Reekum; Kitty W M Bloemenkamp; Nine V A M Knoers; Albertien M van Eerde; A Titia Lely
Journal:  Nephron       Date:  2020-02-24       Impact factor: 2.847

Review 2.  Pre-conception counselling for key cardiovascular conditions in Africa: optimising pregnancy outcomes.

Authors:  Liesl Zühlke; Letitia Acquah
Journal:  Cardiovasc J Afr       Date:  2016 Mar-Apr       Impact factor: 1.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.